中文摘要 i
Abstract ii
目錄 iii
圖目錄 viii
表目錄 xi
附圖目錄 xii
附表目錄 xiii
第一章　緒論 - 1 -
第一節　頭頸癌（Head and neck cancer） - 1 -
第二節　口腔癌（Oral cancer） - 1 -
第三節　口腔癌分期 - 2 -
第四節　口腔癌目前治療方式 - 3 -
第五節　口腔癌的預後 - 4 -
第六節　厚朴酚（Magnolol） - 4 -
第七節　2-O-methylmagnolol （MM1） - 5 -
第八節　長鏈非編碼核糖核酸 （Long non-coding RNA, lncRNA） - 6 -
第九節　上皮間質轉化 （Epithelial-mesenchymal transition, EMT） - 7 -
第十節　信號轉導及轉錄激活蛋白3 （Signal transducer and activator of transcription 3, STAT3） - 7 -
第二章　研究目的 - 9 -
第三章　實驗設計與方法 - 10 -
第一節　細胞株及細胞培養 - 10 -
壹、細胞株（Cell lines） - 10 -
貳、細胞株培養（Cell culture） - 10 -
參、細胞繼代培養（Subculture） - 11 -
肆、細胞數測定 （Cell counting） - 11 -
第二節　試劑（Reagents） - 12 -
壹、藥物及試劑（Drugs and reagents） - 12 -
貳、抗體（Antibodies） - 13 -
參、質體（Plasmid） - 13 -
第三節　實驗方法（Methods） - 13 -
壹、Sulforhodamine B（SRB）colorimetric assay - 13 -
貳、細胞存活測試（Trypan blue staining） - 14 -
參、細胞群落生成試驗（Clonogenic survival assay） - 15 -
肆、細胞遷移試驗（Cell migration assay） - 15 -
伍、細胞侵襲試驗（Cell invasion assay） - 16 -
陸、西方墨點法（Western blot） - 16 -
一、細胞中蛋白質的萃取（Protein extraction） - 16 -
二、蛋白質定量（Protein quantification） - 17 -
三、膠凝體電泳（Sodium dodecyl sulfate polyacrylamide gel electrophoresis，SDS-PAGE） - 17 -
四、轉漬（Transfer） - 18 -
五、免疫墨點（Immuno blot） - 18 -
柒、核糖核酸萃取 （RNA extraction） - 19 -
捌、反轉錄聚合酶鏈鎖反應（Reverse transcription-PCR, RT-PCR） - 20 -
一、反轉錄反應（Reverse Transcription） - 20 -
二、聚合酶酵素鏈鎖反應（Polymerase Chain Reaction） - 20 -
三、即時定量反轉錄聚合連鎖反應（Real-time quantitative reverse transcription PCR） - 21 -
玖、細胞轉染（Transfection） - 21 -
拾、建立帶有螢光素酶（Luciferase）的細胞株 - 22 -
一、選殖細胞（Selection of stable cell lines） - 22 -
二、螢光素酶試驗（Luciferase assay） - 22 -
拾壹、體內原位移植瘤模型（In vivo orthotopic tumor implantation model） - 22 -
拾貳、免疫組織化學染色（Immunohistochemistry） - 23 -
拾參、組織化學染色–蘇木紫-伊紅染色（Hematoxylin and eosin stain） - 24 -
拾肆、Kaplan-Meier（K-M） survival curve - 24 -
拾伍、藥物聯合作用指數（Drug combination index; CI） - 25 -
拾陸、酵素免疫分析法（Enzyme-linked immunosorbent assay; ELISA assay） - 25 -
拾柒、統計分析（Statistical analysis） - 26 -
第四章　結果 - 27 -
第一節　Magnolol 及 MM1 對於細胞的毒殺作用 - 27 -
第二節　Magnolol 及 MM1 對於細胞的存活率影響 - 27 -
第三節　Magnolol 及 MM1 對於抑制細胞群落形成的效果 - 28 -
第四節　Magnolol 及 MM1 對於細胞遷移的抑制效果 - 29 -
第五節　Magnolol 及 MM1 對於細胞侵襲的抑制效果 - 29 -
第六節　Magnolol 及 MM1 對於口腔鱗狀癌細胞上皮細胞間質轉化（epithelial-mesenchymal transition，EMT）的影響 - 30 -
第七節　Magnolol 及 MM1 使口腔鱗狀癌細胞走向凋亡 - 31 -
第八節　確認 SAS-Luc 細胞中螢光素酶的表現量 - 31 -
第九節　MM1 抑制口腔鱗狀癌細胞 SAS 之活體內腫瘤的生成 - 32 -
第十節　Magnolol 及 MM1 抑制口腔鱗狀癌細胞 STAT3 及 AKT磷酸化蛋白表現 - 33 -
第十一節　Magnolol 及 MM1 對 IL-6 表現的影響 - 34 -
第十二節　MM1 合併臨床化療用藥（cisplatin）觀察對於口腔鱗狀癌細胞 SAS 表現 - 35 -
第十三節　Magnolol 及 MM1 對 long non-coding RNA NEAT1表現的影響 - 35 -
第十四節　MM1 促使小鼠口腔鱗狀細胞癌凋亡 - 36 -
第五章　討論 - 37 -
第六章　圖表 - 44 -
第六章　文獻參考 - 66 -
第七章　附圖表 - 73 -

1.Ko, Y.C., et al., Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med, 1995. 24(10): p. 450-3.
2.Thomas, S.J. and R. MacLennan, Slaked lime and betel nut cancer in Papua New Guinea. Lancet, 1992. 340(8819): p. 577-8.
3.Kalavrezos, N. and C. Scully, Mouth Cancer for Clinicians Part 3: Risk Factors (Traditional: Tobacco). Dent Update, 2015. 42(5): p. 476-8, 480-3.
4.Blot, W.J., et al., Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res, 1988. 48(11): p. 3282-7.
5.Lu, C.T., et al., A case-control study of oral cancer in Changhua County, Taiwan. J Oral Pathol Med, 1996. 25(5): p. 245-8.
6.Brandwein-Gensler, M. and R.V. Smith, Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system. Head Neck Pathol, 2010. 4(1): p. 53-61.
7.Lee, Y.J., et al., Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther, 2011. 130(2): p. 157-76.
8.Ho, K.Y., et al., Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother Res, 2001. 15(2): p. 139-41.
9.Chunlian, W., et al., Magnolol inhibits tumor necrosis factor-alpha-induced ICAM-1 expression via suppressing NF-kappaB and MAPK signaling pathways in human lung epithelial cells. Inflammation, 2014. 37(6): p. 1957-67.
10.Shigemura, K., et al., Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer, 2007. 109(7): p. 1279-89.
11.Chen, C.R., et al., Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice. Br J Pharmacol, 2011. 164(5): p. 1534-46.
12.Zuo, G.Y., et al., In vitro synergism of magnolol and honokiol in combination with antibacterial agents against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). BMC Complement Altern Med, 2015. 15: p. 425.
13.Chen, Y.H., et al., Antioxidative and hepatoprotective effects of magnolol on acetaminophen-induced liver damage in rats. Arch Pharm Res, 2009. 32(2): p. 221-8.
14.Youn, U.J., et al., Cytotoxic lignans from the stem bark of Magnolia officinalis. J Nat Prod, 2007. 70(10): p. 1687-9.
15.Wei, W., et al., Magnolol inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis model. Inflammation, 2015. 38(1): p. 16-26.
16.Chao, L.K., et al., Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen-activated protein kinase, and the NF-kappaB pathway to reduce LPS-induced TNFalpha and NO expression. J Agric Food Chem, 2010. 58(6): p. 3472-8.
17.Liu, Y., et al., The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. Sci Rep, 2013. 3: p. 3098.
18.Zhou, Y., et al., Magnolol induces apoptosis in MCF-7 human breast cancer cells through G2/M phase arrest and caspase-independent pathway. Pharmazie, 2013. 68(9): p. 755-62.
19.Park, J.B., et al., Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway. Biol Pharm Bull, 2012. 35(9): p. 1614-20.
20.Kang, Y.J., et al., Wnt/beta-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells. Mol Pharmacol, 2012. 82(2): p. 168-77.
21.Tsai, J.R., et al., Magnolol induces apoptosis via caspase-independent pathways in non-small cell lung cancer cells. Arch Pharm Res, 2014. 37(4): p. 548-57.
22.Seo, J.U., et al., Anticancer potential of magnolol for lung cancer treatment. Arch Pharm Res, 2011. 34(4): p. 625-33.
23.Li, H.B., et al., Magnolol-induced H460 cells death via autophagy but not apoptosis. Arch Pharm Res, 2007. 30(12): p. 1566-74.
24.Chilampalli, C., et al., Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action. BMC Cancer, 2011. 11: p. 456.
25.Hwang, E.S. and K.K. Park, Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci Biotechnol Biochem, 2010. 74(5): p. 961-7.
26.McKeown, B.T. and R.A. Hurta, Magnolol affects expression of IGF-1 and associated binding proteins in human prostate cancer cells in vitro. Anticancer Res, 2014. 34(11): p. 6333-8.
27.McKeown, B.T., et al., Magnolol causes alterations in the cell cycle in androgen insensitive human prostate cancer cells in vitro by affecting expression of key cell cycle regulatory proteins. Nutr Cancer, 2014. 66(7): p. 1154-64.
28.Cheng, Y.C., et al., Magnolol and honokiol exert a synergistic anti-tumor effect through autophagy and apoptosis in human glioblastomas. Oncotarget, 2016.
29.Kumar, S., et al., Autophagy triggered by magnolol derivative negatively regulates angiogenesis. Cell Death Dis, 2013. 4: p. e889.
30.Ikeda, K., Y. Sakai, and H. Nagase, Inhibitory effect of magnolol on tumour metastasis in mice. Phytother Res, 2003. 17(8): p. 933-7.
31.Lin, C.F., et al., Maximizing dermal targeting and minimizing transdermal penetration by magnolol/honokiol methoxylation. Int J Pharm, 2013. 445(1-2): p. 153-62.
32.Wang, T.H., et al., 2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Cell Death Dis, 2017. 8(3): p. e2638.
33.Wilusz, J.E., H. Sunwoo, and D.L. Spector, Long noncoding RNAs: functional surprises from the RNA world. Genes Dev, 2009. 23(13): p. 1494-504.
34.Kung, J.T., D. Colognori, and J.T. Lee, Long noncoding RNAs: past, present, and future. Genetics, 2013. 193(3): p. 651-69.
35.Jiang, P., et al., NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget, 2016. 7(28): p. 43337-43351.
36.Lau, E., Non-coding RNA: Zooming in on lncRNA functions. Nat Rev Genet, 2014. 15(9): p. 574-5.
37.Wang, K.C. and H.Y. Chang, Molecular mechanisms of long noncoding RNAs. Mol Cell, 2011. 43(6): p. 904-14.
38.Guttman, M., et al., Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature, 2009. 458(7235): p. 223-7.
39.Huarte, M., The emerging role of lncRNAs in cancer. Nat Med, 2015. 21(11): p. 1253-61.
40.Jiang, C., et al., Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis. Mol Cancer, 2016. 15(1): p. 62.
41.Song, S., et al., RCCRT1 is correlated with prognosis and promotes cell migration and invasion in renal cell carcinoma. Urology, 2014. 84(3): p. 730 e1-7.
42.Guttman, M., et al., lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature, 2011. 477(7364): p. 295-300.
43.de Lena, P.G., et al., Clusterization in head and neck squamous carcinomas based on lncRNA expression: molecular and clinical correlates. Clin Epigenetics, 2017. 9: p. 36.
44.Kalluri, R. and R.A. Weinberg, The basics of epithelial-mesenchymal transition. J Clin Invest, 2009. 119(6): p. 1420-8.
45.Tiwari, N., et al., EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol, 2012. 22(3): p. 194-207.
46.Linher-Melville, K. and G. Singh, The complex roles of STAT3 and STAT5 in maintaining redox balance: Lessons from STAT-mediated xCT expression in cancer cells. Mol Cell Endocrinol, 2017.
47.Chen, S.C., et al., Herbal remedy magnolol suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells. Br J Pharmacol, 2006. 148(2): p. 226-32.
48.Nathanson, A., et al., Evaluation of some prognostic factors in small squamous cell carcinoma of the mobile tongue: a multicenter study in Sweden. Head Neck, 1989. 11(5): p. 387-92.
49.Vichai, V. and K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc, 2006. 1(3): p. 1112-6.
50.Chou, T.C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res, 2010. 70(2): p. 440-6.
51.Im, A.R., et al., Magnolol reduces UVB-induced photodamage by regulating matrix metalloproteinase activity. Environ Toxicol Pharmacol, 2015. 39(1): p. 417-23.